<DOC>
	<DOCNO>NCT00517881</DOCNO>
	<brief_summary>This single arm study ass efficacy , safety tolerability subcutaneous methoxy polyethylene glycol-epoetin beta ( C.E.R.A . ) maintenance hemoglobin level pre-dialysis participant chronic renal anemia . Participants currently receive maintenance treatment subcutaneous darbepoetin alfa receive monthly subcutaneous injection C.E.R.A . start dose 120 , 200 360 microgram ( mcg ) derive dose darbepoetin alfa epoetin alfa week precede study start .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Study Subcutaneous C.E.R.A . Pre-Dialysis Participants With Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Chronic renal anemia Hemoglobin concentration 10.5 gram per deciliter ( g/dL ) 12.5 g/dL Adequate iron status ( serum ferritin great [ &gt; ] 100 nanogram per milliliter Transferrin Saturation &gt; 20 percent [ % ] hypochromic red cell less [ &lt; ] 10 % ) Continuous subcutaneous maintenance darbepoetin alfa therapy dose interval previous 2 month Transfusion red blood cell previous 2 month Poorly control hypertension require hospitalization interruption darbepoetin alfa treatment previous 6 month Acute chronic bleed Active malignant disease ( except nonmelanoma skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>